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Key points 
Chk, Csk and PTPRJ are the main regulators of SFKs in platelets, which play a key role in 
maintaining platelet count. 
 
SFKs are able to auto-regulate their activity by phosphorylating either their activation loop or 
C-terminal inhibitory tyrosine residue. 
 
Abstract 
The Src family kinases (SFKs) Src, Lyn and Fyn are essential for platelet activation and also 
involved in megakaryocyte (MK) development and platelet production.  Platelet SFKs are 
inhibited by C-terminal Src kinase (Csk), which phosphorylates a conserved tyrosine in their 
C-terminal tail, and are activated by the receptor-type tyrosine phosphatase PTPRJ (CD148, 
DEP-1), which dephosphorylates the same residue.  Deletion of Csk and PTPRJ in the MK 
lineage in mice results in increased SFK activity, but paradoxically hypoactive platelets due to 
negative feedback mechanisms, including upregulation of Csk homologous kinase (Chk) 
expression.  Here, we investigate the role of Chk in platelets, functional redundancy with Csk 
and the physiological consequences of ablating Chk, Csk and PTPRJ in mice.  Platelet count 
was normal in Chk knockout (KO) mice, reduced by 92% in Chk;Csk double KO (DKO) mice, 
and partially rescued in Chk;Csk;Ptprj triple KO (TKO) mice.  Megakaryocyte numbers were 
significantly increased in both DKO and TKO mice.  Phosphorylation of the inhibitory tyrosine 
of SFKs was almost completely abolished in DKO platelets, which was partially rescued in Src 
and Fyn in TKO platelets.  This residual phosphorylation was abolished by Src inhibitors, 
revealing an unexpected mechanism in which SFKs auto-inhibit their activity by 
phosphorylating their C-terminal tyrosine residues.  We demonstrate that reduced inhibitory 
phosphorylation of SFKs leads to thrombocytopenia with Csk being the dominant inhibitor in 
platelets, and Chk having an auxiliary role.  PTPRJ deletion in addition to Chk and Csk 
ameliorates the extent of thrombocytopenia, suggesting targeting it may have therapeutic 
benefits in such conditions.  
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Introduction 
Src family kinases (SFKs) are essential for initiating and propagating activation signals from a  
variety of platelet receptors, including the immunoreceptor tyrosine-based activation motif 
(ITAM)-containing collagen receptor complex GPVI-FcR γ-chain and the fibrinogen receptor 
integrin αIIbβ3.1  SFKs also initiate inhibitory signaling from immunoreceptor tyrosine-based 
inhibitory motif (ITIM)-containing receptors, including the megakaryocyte and platelet 
inhibitory receptor G6b-B (MPIG6B) and platelet endothelial cell adhesion molecule 
(PECAM-1).2,3  In platelets, SFKs are regulated by C-terminal Src kinase (Csk), which 
phosphorylates a conserved tyrosine residue in the C-terminal tail of SFKs, restraining them in 
an inactive conformation; and by the receptor-type tyrosine phosphatase PTPRJ (CD148, DEP-
1, RPTPη), which dephosphorylates the same tyrosine residue, thereby releasing SFKs from 
their auto-inhibited conformation.2,4-6  Trans-auto-phosphorylation of a conserved tyrosine 
residue in their activation loop stabilizes the active conformation.  PTPRJ is also able to 
attenuate SFK activity by dephosphorylating the activation loop tyrosine.2,6-8  Targeted deletion 
of Csk and Ptprj in the megakaryocyte (MK) lineage of mice results in significantly elevated 
SFK activity, but paradoxical hypo-active platelets, reduced thrombosis and increased 
bleeding, due to negative feedback pathways, including downregulation  of GPVI-FcR γ-chain 
and the hemi-ITAM-containing podoplanin receptor CLEC-2, and concomitant upregulation 
and phosphorylation of the inhibitory receptor MPIG6B.2 
Src and Lyn also play important roles in MK development and platelet production as 
exemplified by human and mouse genetic studies.  The gain-of-function mutation in human 
Src (E527K), resulting in loss of Src auto-inhibition, causes thrombocytopenia and a reduction 
in proplatelet formation.9,10  Moreover, Lyn knockout (KO) mice display increased MK 
progenitor cell proliferation and a greater number of mature MKs with increased ploidy in vitro 
and more MKs in the bone marrow.11-13  Although, Lyn KO and Src KO mice do not display 
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major differences in platelet count compared to control mice due to the overlapping roles of 
these SFKs, mice deficient in both Lyn and Src develop thrombocytopenia.14  The critical role 
of Src and Lyn in MK maturation and proplatelet formation is further consolidated by tyrosine 
kinase inhibitor studies.  Pharmacological inhibition of SFKs by PP1, PP2, SU6656 or dasatinib 
results in enhanced proliferation and maturation of cultured megakaryocytes,11,15,16 and 
increased platelet production of inhibitor-treated MKs infused to mice in vivo.17 
The two main regulators of platelet SFKs, namely Csk and PTPRJ, also play key roles 
in MK function and platelet production.  Pf4-Cre-generated Csk KO mice display a 65% 
reduction in platelet count, whereas Gp1ba-Cre-generated Csk KO mice, in which 
recombination occurs later in  MK development, show a 32% decrease in platelet count, 
highlighting a key role of Csk in MK development and platelet production.2,18  However, Ptprj 
KO mice have normal platelet counts, MKs from these mice display reduced spreading on 
collagen-, fibrinogen- and fibronectin-coated surfaces and are unable to migrate towards an 
SDF-1α gradient.5  Csk;Ptprj double KO (DKO) mice also present normal mean platelet 
counts, demonstrating that the deletion of Ptprj rescues the platelet count phenotype of Csk KO 
mice, as well as MK counts in the bone marrow (BM).2  Recently, biallelic loss-of-function 
mutations in Ptprj (g.48131608A>G and g.48158556delG) were described in patients,  
resulting in a novel form of inherited thrombocytopenia, characterized by impaired maturation 
of MKs and reduced platelet volume, further highlighting the importance of PTPRJ to MK 
development and function.19 
We previously showed that phosphorylation of the C-terminal inhibitory tyrosine 
residues of SFKs was partially rescued in platelets lacking both Csk and PTPRJ, suggesting 
that another kinase can compensate for Csk.2  We found that Csk homologous kinase (Chk, 
also known as megakaryocyte-associated tyrosine kinase, Matk), is upregulated in these 
platelets and thus might partially fulfil the function of Csk.2  Chk shares approximately 50% 
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homology with Csk, with restricted expression in neuronal cells in the brain and hematopoietic 
cells.  Chk was previously detected in platelets by Western blotting, but not by mass 
spectrometry-based approaches, suggesting low levels of expression.20-22  This correlated with 
the lack of a platelet or hemostatic phenotype in Chk KO mice drawing into question the 
functional relevance of Chk in platelets.23  Chk has been implicated in MK progenitor 
formation by using antisense oligonucleotides to reduce protein expression.24  In addition, 
overexpression of Chk lead to a reduction in agonist-induced SFK activity in megakaryocytic 
cell lines,25 and the protein was also implicated in cell spreading,26 however,  in vivo data  is 
lacking.23,27,28 
In this study, we have generated and analysed Chk KO mice alongside Chk;Csk DKO 
and Chk;Csk;Ptprj triple KO (TKO) mice, to determine if there is functional redundancy 
between Chk and Csk and whether the lack of PTPRJ can rescue MK and platelet phenotypes. 
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Methods 
Mice 
Matktm1Sor knockout (Chk KO) mice were from the Jackson Laboratories.  Cskfl/fl, Ptprjfl/fl, and 
Pf4-Cre+ mice were generated, as previously described.29-31  All mice were on a C57BL/6 
background.  Pf4-Cre+ mice were used as control mice.  All procedures were undertaken with 
United Kingdom Home Office approval in accordance with the Animals (Scientific 
Procedures) Act of 1986. 
 
Antibodies and reagents 
Anti-CD42a antibody was from Abcam; anti-Shp1, anti-Shp1 p-Tyr564, anti-Shp2 and anti-
Shp2 p-Tyr580 antibodies were from Cell Signaling Technology; anti-mouse TLT-1 Alexa 
Fluor-488 antibody was from R&D systems.32  Fluorescein peanut agglutinin was from Vector 
Laboratories.  Dasatinib was from LC laboratories, PP1 was from Calbiochem and PRT-
060318 was from SynKinase.  Other antibodies and reagents were previously described.2  
 
Platelet preparation 
Washed platelets were prepared as described.2  Platelet concentration was normalized at 2 x 
107/ml for spreading and flow cytometry analysis, and 5 x 108/ml for biochemical analysis.    
 
Saline tail bleeding time assay 
Mice were anesthetized using isoflurane and 3 mm of the tail tip was cut off.  Immediately, 
tails were immersed in 0.9% isotonic saline at 37 °C.  The time to complete arrest of bleeding 
(no blood flow for 1 minute) was determined.  If on/off cycles of bleeding occurred, the sum 
of bleeding times within a 20-minute period was used.  Otherwise, experiments were stopped 
after 20 minutes. 
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Immunohistochemistry, platelet functional assays and biochemistry 
Immunohistochemistry, platelet adhesion, stimulation for flow cytometry and immunoblotting 
by ProteinSimple Wes are described in detail in the supplemental Methods. 
 
Statistical analysis 
Data presented are means ± standard deviation (SD).  One-way or two-way ANOVA followed 
by appropriate post-hoc test were used to determine statistical significance (P < .05). 
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Results 
Severe macrothrombocytopenia in Chk;Csk DKO mice 
Constitutive Chk KO (CKO) mice were crossed with Cskfl/fl;Pf4-Cre+ mice, in which Csk was 
conditionally deleted, to generate Chk;Csk DKO mice.  DKO mice were further crossed with 
Ptprjfl/fl mice to generate Chk;Csk;Ptprj TKO mice in which Chk is deleted in every cell, 
whereas Csk and PTPRJ are deleted in MKs, platelets and subsets of leukocytes due to 
leakiness of the Pf4-Cre transgene, as previously described.18  We detected Chk expression in 
control mouse platelets by quantitative capillary electrophoresis-based immunoassays 
(ProteinSimple Wes), which was absent in CKO, DKO and TKO mice (Figure 1A-B).  Csk 
expression was reduced to 6% in DKO and to 1% in TKO platelets compared to control 
platelets (Figure 1A-C).  Surface expression of PTPRJ was reduced to 11% in TKO platelets, 
however, DKO platelets displayed a mean increase of 166% in PTPRJ surface expression, 
possibly as a compensatory feedback mechanism (Figure 1D).  Platelet counts were normal in 
CKO mice, however DKO mice displayed severe thrombocytopenia with a 92% reduction in 
platelet counts compared to control mice (Figure 1E and Table S1).  This is a further 27% 
decrease compared with Csk KO mice, previously reported to have a 65% reduction in platelet 
count.2  Intriguingly, TKO mice had only a 34% reduction in platelet count compared with 
controls, demonstrating a partial rescue of the DKO phenotype in the absence of PTPRJ (Figure 
1E).  Mean platelet volume was not significantly different in CKO mice, whereas it was 
increased 49% in DKO mice and 23% in TKO mice (Figure 1F).  The spleen/body weight ratio 
was also increased by 244% in DKO mice and 115% in TKO mice (Figure 1G), suggesting 
extramedullary hematopoiesis.  These results demonstrate that while Csk can compensate for 
the loss of Chk in CKO mice, when both kinases are absent, DKO mice develop a more severe 
thrombocytopenia compared to Csk KO mice, suggesting redundancy in regulating platelet 
count. 
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Aberrant megakaryocyte counts and associated myelofibrosis in DKO and TKO mice 
Histological analysis of main sites of thrombopoiesis, namely the bone marrow, spleen and 
lung, revealed major differences in MK counts in DKO and TKO mice.  We found a 44% 
increase in MK count per field of view in TKO bone marrow and a 49% increase when counted 
the total number of MKs per section, but no difference in MK numbers in CKO or DKO bone 
marrow compared to control mice (Figure 2A, D-E).  Notably, MKs in DKO and TKO bone 
marrow appeared atypical.  Furthermore, we found an over 6-fold increase in MK numbers per 
field of view in the spleen of both DKO and TKO mice (Figure 2B and E).  The total number 
of MKs per spleen section increased by over 13-fold in DKO and by over 8-fold in TKO mice 
(Figure 2D).  A marginal increase in the number of CD42b+ cells was observed in the lungs of 
DKO and TKO mice (Figure 2C-D), which may be MKs or MK fragments as a consequence 
of increased megakaryopoiesis and release from the bone marrow and spleens of these mice.  
We also observed associated paratrabecular and perivascular reticulin staining in the bone 
marrow and a marginal increase in reticulin staining in the spleen of DKO and TKO mice 
(Figure 2A-B), indicative of fibrosis.   
 
Reduction in the level of GPVI and CLEC-2 in DKO and TKO platelets 
To investigate whether changes in platelet count correlate with altered platelet receptors, we 
quantified surface levels of receptors responsible for platelet production and activation.  We 
found a 21-24% increase in αIIbβ3 levels in DKO and TKO platelets, and 21% decrease in α2 
levels in DKO platelets (Figure 3A).  GPIbα levels were increased by 82% in DKO platelets, 
which plays a central role in regulating platelet size and count.33  Surface expression of the 
ITAM-containing GPVI receptor was reduced by 77% and by 97% in DKO and TKO platelets, 
respectively (Figure 3A).  Moreover, surface expression of the hemi-ITAM-containing CLEC-
2 receptor was reduced by 43% and 79% in DKO and TKO platelets, respectively.  Platelet 
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surface expression of the inhibitory ITIM-containing MPIG6B receptor was reduced by 23% 
in CKO platelets and increased by 44% in TKO platelets.  These data suggest that Chk plays a 
role in regulating surface expression of ITAM-containing receptors, as previously established 
for Csk and PTPRJ.2 
 
Increased platelet turnover and pre-activation in DKO and TKO mice 
To further investigate the cause of thrombocytopenia in DKO and TKO mice, we assessed the 
fraction of immature reticulated, desialylated and pre-activated platelets in whole blood from 
these mice.  All of these parameters were similar in CKO and control mice (Figure 3B-F).  
However, we found 4- and 2-fold increases in reticulated platelets in DKO and TKO mice 
respectively compared with control mice, suggesting a higher percentage of young platelets in 
the circulation of these mice (Figure 3B-C).  Platelet staining with peanut agglutinin (PNA) 
lectin, which specifically binds to exposed galactose residues, was used as a marker of 
desialylation of surface glycans, and is associated with old platelets.34  We found a 74% 
increase in PNA binding to DKO platelets, and a 50% increase to TKO platelets, compared to 
controls (Figure 3D-E).  We next stained resting platelets for different activation markers.  We 
observed a 52-fold increase in the percentage of P-selectin positive platelets in TKO blood 
(Figure 3F), suggesting platelet pre-activation.  Notably, we detected 8- and 7-fold increases 
in surface TLT-1 levels in DKO and TKO platelets, respectively compared to control (Figure 
3F), providing further evidence of platelet pre-activation in these mice.  We also observed 2- 
and 5-fold increases in fibrinogen binding in DKO and TKO platelets, respectively, compared 
with platelets from control mice, suggesting the integrin αIIbβ3 was in a high affinity, active 
conformation in a proportion of these platelets.  We found only a minor increase in the 
percentage of Annexin V positive platelets in blood from DKO mice (Figure 3F).  Increased 
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megakaryocyte counts and immature platelet fraction suggests impaired platelet production in 
DKO mice, which was partially restored in TKO mice. 
 
Platelet functional defects in DKO mice are rescued in TKO mice 
Due to the severe thrombocytopenia in DKO mice, we were only able to test platelet function 
in a limited set of assays.  Platelet α-granule secretion and integrin αIIbβ3 activation were 
assessed by measuring P-selectin and TLT-1 surface expression and fibrinogen binding, 
respectively by flow cytometry.  PAR4 peptide-stimulated CKO platelets expressed similar 
increase in P-selectin and TLT-1 levels and displayed comparable elevation of fibrinogen 
binding as stimulated control platelets (Figure 4A and Figure S1).  In contrast, DKO platelets 
exhibited significant impairment in staining for all three markers (Figure 4A).  Interestingly, 
PAR4 peptide-stimulated TKO platelets showed a similar increase in P-selectin expression and 
fibrinogen binding as control platelet, despite higher basal expressions of these markers in 
whole blood (Figure 3F), however there was a minor reduction in TLT-1 expression (Figure 
4A), presumably as a consequence of activation of inhibitory mechanisms.32 
We next analysed platelet spreading on a fibrinogen coated surface, as a means of 
assessing integrin αIIbβ3 function.  Resting platelets were either directly plated on fibrinogen, 
or were pre-activated with 0.1 U/ml thrombin prior to plating.  CKO platelets spread 
comparably to control platelets, whereas DKO platelets displayed a 28% increase in spreading 
(Figure 4B-C).  However, in the presence of thrombin, there was no significant difference 
between control and DKO platelets.  Although TKO platelets spread to a similar extent as 
control platelets, the morphology of thrombin activated TKO platelets was different compared 
to control platelets, with reduced lamellipodia and stress fibre formation (Figure 4B). 
We next assessed the haemostasis in the various mouse models using the saline tail 
bleeding assay.  We found no significant difference in bleeding time of CKO mice compared 
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with control mice (Figure 4D).  In agreement with the 92% reduction in platelet count in DKO 
mice (Figure 1E), we observed significant bleeding in these mice (Figure 4D).  This bleeding 
phenotype was rescued in TKO mice, which displayed no significant difference in bleeding 
time compared with control mice (Figure 4D).  We conclude that the partially rescued platelet 
count in combination with the almost normal platelet reactivity in response to thrombin 
receptor stimulation is sufficient to restore haemostatic function in TKO mice. 
 
Partial rescue of Src and Fyn inhibitory tyrosine phosphorylation in TKO platelets 
To study the biochemical consequences of ablating Chk, Csk and PTPRJ, we assessed tyrosine 
phosphorylation of SFKs in resting platelets by a capillary electrophoresis-based 
immunoassay.  We measured phosphorylation of the activation loop tyrosine residue of SFKs 
(Src p-Tyr418), an indirect indicator of SFK activity, which was normal in CKO and DKO, 
and increased 75% in TKO platelets (Figure 5A-B), possibly due to increased PTPRJ 
expression, which can dephosphorylate Src p-Tyr418 and attenuate activity (Figure 1D).  We 
then measured phosphorylation of the C-terminal inhibitory tyrosine residues of Src, Lyn and 
Fyn, which binds intra-molecularly with their SH2 domain, locking the kinases in an inactive 
conformation.  We observed an 80-92% decrease of Src p-Tyr529, Lyn p-Tyr507 and Fyn p-
Tyr530 in DKO platelets compared with controls (Figure 5A-B).  There was a 4-fold increase 
in Src p-Tyr529 and a 2-fold increase in Fyn p-Tyr530 in TKO platelets compared to DKO 
platelets, but no significant difference in Lyn p-Tyr507.  These residues were phosphorylated 
to the same extent in CKO platelets.  These findings suggest that another kinase can 
phosphorylate these inhibitory tyrosine residues in the absence of Chk and Csk.  In addition, 
we found that Src, Lyn and Fyn all exhibited some degree of regulation on the protein level in 
DKO or TKO platelets.  Whereas Src levels were increased by 134% in DKO platelets, Lyn 
and Fyn levels were reduced by 65% and 34%, respectively in TKO platelets compared to 
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controls (Figure 5A-B).  Moreover, expression of the tyrosine kinase Syk was also found to be 
reduced in TKO platelets by 37%. 
We next assessed the regulation of the cytosolic tyrosine phosphatases Shp1 and Shp2, 
both of which contain two conserved C-terminal tyrosine residues, phosphorylation of which 
has been implicated in regulating downstream signalling.35-37  We found Shp1 p-Tyr564 to be 
increased by 6- and 10-fold in DKO and TKO platelets, respectively.  However, DKO platelets 
also showed a 3-fold increase in Shp1 protein levels.  Shp2 p-Tyr580 was increased by 5-fold 
in DKO platelets and 7-fold in TKO platelets (Figure 5A-B).  These findings demonstrate that 
SFKs lie upstream of Shp1 and Shp2, acting either directly or indirectly, to activate these 
phosphatases. 
 
SFKs auto-phosphorylate their C-terminal inhibitory tyrosine residues 
To explore which other kinases phosphorylate the C-terminal tyrosine residues of SFKs, we 
incubated control and TKO platelets with two different SFK inhibitors, namely dasatinib and 
PP1, and the Syk kinase inhibitor PRT-060318.16,38  Dasatinib and PP1 significantly reduced 
Src p-Tyr418 in control and TKO platelets, whereas PRT-060318 had only a minor effect, as 
expected.  We found that dasatinib reduced Src p-Tyr529, Lyn p-Tyr507 and Fyn p-Tyr530 in 
TKO platelets by 52-62%, and PP1 reduced phosphorylation of these sites by 64-73% (Figure 
6A-B).  These findings suggest that SFKs themselves are able to phosphorylate their C-terminal 
inhibitory tyrosine residues in the absence of Chk and Csk, thus auto-inhibiting their activity 
(Figure 7).  However, PRT-060318 had no significant effect on phosphorylation of these 
residues in TKO platelets, suggesting Syk plays no role in phosphorylating these residues. 
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Discussion 
In the present study, we investigated the physiological functions of Chk, Csk and PTPRJ in 
platelets.  By analysing mice lacking Chk alone, or in combination with Csk and PTPRJ, we 
demonstrate that Chk and Csk have redundant functions inhibiting SFKs in the MK lineage 
(Figure 7), with Csk playing the dominant role, and that PTPRJ plays a central role in both 
activating and attenuating SFK activity.  DKO mice developed severe macrothrombocytopenia 
with a 92% drop in platelet count, elevated MK numbers and immature platelet fraction, 
pointing to disruption of platelet production.  Platelet counts in DKO mice were considerably 
lower than in Csk KO mice, whereas MK numbers in the spleen and immature platelet fraction 
were double (Table 1).2  These phenotypes suggest that Csk can fully compensate for the 
absence of Chk in MKs and platelets, whereas Chk can compensate only in part in the absence 
of Csk.  DKO mice revealed that Chk and Csk are essential for platelet production.  TKO mice 
showed partially restored platelet counts, elevated MK numbers in the bone marrow and spleen, 
and an immature platelet fraction that was between control and DKO mice.  These findings 
together with our previous report demonstrating rescued platelet counts in the Csk;Ptprj DKO 
mice compared to Csk KO mice, highlight that by controlling the extent of phosphorylation of 
the C-terminal inhibitory tyrosine residues of SFKs, PTPRJ plays a central role in regulating 
platelet counts and activation (Figure 7, Table 1).2 
 Biallelic loss-of-function mutations in Ptprj has recently been suggested to cause a 
novel form of inherited thrombocytopenia humans.19  Although most of the human findings 
correlate with results from Ptprj-deficient mice, significant reduction in the platelet count is 
not observed in constitutive Ptprj loss-of-function transmembrane KO mice or in conditional 
KO mice generated with either the Pf4-Cre or Gp1ba-Cre transgenes (Figure S2).2,5,18 
Although the cause of these apparent differences is not known, we hypothesize this is primarily 
due to epigenetic effects and modifier loci in the patients that is not the case in inbred C57Bl/6 
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mice.  Of note, ablation of Ptprj in zebrafish resulted in only a minor drop in thrombocyte 
counts.19  
One of the consequences of increased MK count is the development of myelofibrosis, 
which was observed in the bone marrow of DKO and TKO mice, but not in Csk KO or 
Csk,Ptprj DKO mice (Table 1).  Primary myelofibrosis is a rare heterogeneous disorder with 
poor prognosis in which somatic mutations drive clonal expansion of hematopoietic stem cells; 
and is characterized by bone marrow fibrosis, MK proliferation and atypia, extramedullary 
hematopoiesis and splenomegaly.  Since MKs play a central role in the development of 
myelofibrosis,39,40 and PTPRJ plays a central role in regulating MK function,2,5,19 our findings 
highlight PTPRJ as a potential novel target either alone or in combination with existing 
therapies in the treatment of myeloproliferative neoplasms and myelofibrosis. 
Phosphorylation of C-terminal inhibitory tyrosine residues was barely detectable in 
DKO platelets, which increased significantly in Src and Fyn in TKO platelets, demonstrating 
phosphorylation in the absence of the only two known kinases which are able to phosphorylate 
these sites.41  It also illustrates that PTPRJ must constitutively dephosphorylate these residues, 
even in resting platelets, maintaining a pool of active SFKs in platelets, facilitating rapid 
activation following vascular injury.  We observed that the levels of total Lyn were reduced by 
65% in TKO platelets, which may explain the lack of increase in phosphorylation of Tyr507 in 
its C-terminal tail.  The mechanism for the reduction of Lyn expression is not known, but likely 
involves degradation by the E3 ubiquitin ligase c-Cbl, as previously described in immune 
cells.42  Inhibition of an analog-sensitive variant of Csk induced robust c-Cbl phosphorylation 
and rapid LynA degradation in macrophages.42  In spite of the lack of C-terminal inhibitory 
phosphorylation of SFKs in DKO platelets, we did not observe a significant increase in their 
activation loop phosphorylation.  The reason for this could be the significant increase in PTPRJ 
levels in these platelets, which is able to dephosphorylate the activation loop tyrosine of SFKs, 
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in addition to the C-terminal inhibitory tyrosine residues.2,6  The increase in Shp1 p-Tyr564 
and Shp2 p-Tyr580 suggests elevated inhibitory signaling in DKO and TKO platelets.  Shp1 
phosphorylation has previously been shown to be increased in macrophages expressing a 
hyperactive variant of Lyn and to be diminished in Lyn KO cells.43  Specifically, Lyn has been 
demonstrated to be the predominant kinase phosphorylating Shp1 p-Tyr564 site.44  Src was 
also shown to directly phosphorylate Shp1.35  In addition, thrombin induced Shp1 
phosphorylation was absent in the presence of SFK inhibitors in platelets.45  Similarly, Shp2 
p-Tyr580 may also be a direct substrate of SFKs.  These studies suggest that SFK activity was 
indeed elevated in DKO platelets, despite normal phosphorylation of the SFK activation loop 
tyrosine residue. 
Inhibitor studies using TKO platelets indicate that SFKs are capable of auto-
phosphorylating their C-terminal tails and presumably auto-inhibiting activity (Figure 7B).  In 
addition to SFKs, both PP1 and Dasatinib inhibit Csk at higher concentrations, whereas the 
latter also blocks the activity of the tyrosine kinases Btk, Tec and Abl.46-48  Although, we cannot 
exclude the possibility that inhibition of Btk, Tec or Abl may contribute to the reduction of C-
terminal inhibitory site phosphorylation of SFKs in the Dasatinib-treated samples, the activity 
of these kinases should not be affected in the PP1-treated samples.  Interestingly, we also 
observed a significant decrease in the inhibitory site phosphorylation of Src, Lyn and Fyn in 
control platelets incubated with SFK inhibitors, which may be the consequence of the 
combined decrease in SFK and Csk activities.  We hypothesize that the auto-inhibitory function 
is particularly important as a means of preventing excessive and prolonged SFK activation in 
both unstimulated and ligand-mediated receptor clustering conditions. 
As SFKs are ubiquitously expressed, auto-phosphorylation of their C-terminal 
inhibitory site has previously not appreciated, broad implications for several cell types.41,49  
Indeed, deletion of Chk alone had no detectable effect on phosphorylation of the C-terminal 
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inhibitory tyrosine residues of SFKs in platelets, demonstrating that Csk and auto-inhibition is 
sufficient to prevent aberrant SFK activation.  Residual SFK-mediated auto-phosphorylation 
of the inhibitory tyrosine residues in the absence of Chk, Csk and PTPRJ correlated with 
normal bleeding in these mice, providing evidence of the physiological relevance of this 
mechanism.  The kinetics of phosphorylation of these two regulatory tyrosine residues requires 
further investigation to better understand how SFKs auto-regulate their activity.  Previous work 
from T cells has revealed a complex interplay between membrane localization and 
phosphorylation of these residues in T cell receptor signalling, requiring further investigation 
in platelets.50 
Both DKO and TKO platelets showed signs of pre-activation in the absence of stimuli, 
highlighted by increased TLT-1 expression and fibrinogen binding.  Interestingly, in response 
to PAR4 stimulation, TKO platelets were able to secrete their granules and bind fibrinogen 
similarly to control platelets, possibly due to the remaining inhibitory phosphorylation of SFKs.  
This may also be the result of elevated Shp1 and Shp2 inhibitory activity, via the ITIM-
containing receptor MPIG6B.2,51-53  In contrast, DKO platelets lacking phosphorylation of the 
C-terminal inhibitory tyrosine residues of SFKs were unable to respond to thrombin receptor 
stimulation.  As a consequence of reduced platelet count and reactivity, DKO mice exhibited 
significantly increased tail bleeding, whereas TKO mice responded similar to control mice in 
this assay.  Increased PNA staining of platelets from DKO and TKO mice, indicative of 
increased de-sialylation of surface glycans, suggested aberrant platelet turnover, with a 
population of platelets remaining in the circulation longer than normal.  Intriguingly, we 
observed significant downregulation of (hemi-)ITAM containing receptors in TKO platelets 
with only 3% of GPVI levels and 21% of CLEC-2 levels.  These findings reinforce the key role 
of SFKs in regulating surface GPVI and CLEC-2 levels previously observed in Csk KO and 
Csk;Ptprj DKO platelets (Table 1),2 which might be explained by potentially increased 
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activation of c-Cbl.42  Alternatively, decreased GPVI and CLEC-2 levels might be a 
consequence of platelet pre-activation.  Of note, concomitant deletion of these (hemi-)ITAM-
containing receptors in mice has previously been shown to result in a profound bleeding 
diathesis,54 which is likely counter-acted by elevated SFK activity in TKO platelets. 
In summary, we demonstrated a critical role for Chk, Csk and PTPRJ in platelet 
homeostasis.  Although, Chk was previously implicated in MK maturation, in vivo evidence 
was lacking.23-28  In our study, we demonstrate no megakaryocyte or platelet functional defects 
in CKO mice.  However, DKO mice developed severe macrothrombocytopenia, elevated MK 
counts and immature platelet fraction and myelofibrosis, pointing to an important role of Chk 
and Csk in regulation of platelet counts.  Importantly, additional deletion of PTPRJ from MKs 
and platelets partially corrected platelet counts and immature platelet fraction.  As tyrosine 
phosphatases are increasingly considered druggable, targeting PTPRJ might serve as an 
alternative strategy to regulate platelet counts in instances of high SFK activity.55  We have 
also identified a novel inhibitory mechanism, involving auto-phosphorylation of the C-terminal 
inhibitory tyrosine residues of SFKs, which likely plays an important role in regulating these 
kinases in other cell types, including immune and cancer cells.  In platelets, the partially rescued 
inhibitory phosphorylation and elevated platelet counts preserved the ability of platelets to 
respond to stimuli and restored haemostasis. 
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Table 1.  Summary of Chk, Csk and Ptprj knockout mouse phenotypes 
 
 
↑ upregulated, ↓ downregulated, — normal 
 
 
  
Phenotype 
Genotype 
Chk 
KO 
Csk  
KO2 
Ptprj 
KO2,5 
Chk; 
Csk 
DKO 
Csk; 
Ptprj 
DKO2 
Chk; 
Csk; 
Ptprj 
TKO 
Platelet count — ↓↓ — ↓↓↓ — ↓ 
Reticulated platelets — ↑ — ↑↑↑ ↑ ↑ 
MK count       
     Bone marrow — ↑ — — — ↑ 
     Spleen — ↑↑ ↑ ↑↑↑ ↑↑ ↑↑↑ 
Splenomegaly — ↑ — ↑↑↑ ↑ ↑ 
Myelofibrosis in bone marrow — — — ↑↑ — ↑↑ 
SFK activity — ↑ ↓↓ — ↑↑ ↑ 
Platelet receptor expression       
     GPIbα — ↑↑ — ↑↑ ↑ — 
     GPVI — ↓↓ ↓ ↓↓ ↓↓ ↓↓↓ 
     CLEC-2 — ↓ — ↓ ↓↓ ↓↓ 
     MPIG6b-B  ↓ ↑↑ — — ↑↑ ↑↑ 
Platelet spreading (fibrinogen) — ↑ ↓ ↑ — — 
Bleeding — ↑ — ↑↑↑ ↑↑ — 
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Figures 
Figure 1.  Severe macrothrombocytopenia in DKO mice is partially rescued in TKO mice.  
(A) Representative blots of capillary-based immunoassays on platelet lysates with the indicated 
antibodies.  (B) Representative data from (A) displayed as electropherograms.  (C) 
Quantification of peak areas of Csk signal from (A-B), n = 6 mice/genotype.  (D) Median 
fluorescence intensity (MFI) measured in αIIb+ cells co-stained for PTPRJ in blood, n = 6 
mice/genotype.  (E) Platelet counts, n = 14 mice/genotype.  (F) Platelet volumes, n = 14 
mice/genotype.  (G) Spleen/body weight ratio, n = 15 mice/genotype.  Chk-/- (CKO), Chk-/-
;Cskfl/fl;Pf4-Cre+ (DKO), Chk-/-;Cskfl/fl;Ptprjfl/fl;Pf4-Cre+ (TKO). 
Asterisks refer to significant difference compared to control, or significant difference between 
DKO and TKO.  **P < 0.01, ***P < 0.001, one-way ANOVA with Sidak’s test; mean ± SD. 
 
Figure 2.  Aberrant megakaryocyte counts and myelofibrosis in DKO and TKO mice.   
(A-C) Histological sections of mouse (A) bone marrow, (B) spleen and (C) lung of the 
indicated genotypes stained with H&E, the megakaryocytic marker CD42b or reticulin.  MKs 
are highlighted by yellow arrows.  (D) Total number of MKs per section in the bone marrow 
and spleen, and total number of CD42b+ cell fragments per section in the lung, n = 5 
mice/genotype.  (E) MK numbers per field of view in the indicated organs, n = 5 mice/genotype 
(mean of 15 fields/mouse).  Analysis of MK numbers was performed in a double-blinded 
manner.  
*P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA with Sidak’s test; mean ± SD. 
 
Figure 3.  Reduced expression of (hemi-)ITAM-containing receptors, elevated immature 
platelet fraction and platelet activation markers in DKO and TKO mice.  (A) Median 
fluorescence intensity (MFI) measured in αIIbβ3+ cells or αIIb+ cells co-stained for the 
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indicated proteins in blood, n = 6 mice/genotype.  (B) Representative image of reticulated 
platelet population as measured by flow cytometry.  αIIb+ platelets in whole blood were gated 
and the percentage of reticulated platelets was determined in gate P1 (in red), in dot plot 
diagram forward scatter (FSC) vs RNA dye (Thiazole Orange).  (C) Percentage of reticulated 
platelets as determined in (B).  (D) Representative image of desialylated platelet population.  
αIIb+ platelets in whole blood were gated and the percentage of desialylated platelets was 
determined in gate P1 (in red), in dot plot diagram forward scatter (FSC) vs peanut agglutinin 
(PNA) lectin.  (E) Percentage of desialylated platelets as determined in (D).  (F) Percentage of 
P-selectin+αIIb+, TLT-1+αIIb+, fibrinogen+αIIb+, or Annexin V+αIIb+ cells in blood as 
determined by flow cytometry, n = 6 mice/genotype. 
*P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA with Sidak’s test; mean ± SD. 
 
Figure 4.  Defective platelet activation and hemostasis in DKO mice is restored in TKO 
mice.  (A) Anti-P-selectin-FITC, anti-TREM (triggering receptor expressed on myeloid cells)-
like transcript 1 (TLT-1)-FITC and fibrinogen-488 binding to washed platelets (2 x 107/ml) 
following stimulation with or without PAR4 peptide (AYPGKF) (100 µM or 500 µM, 20 min, 
room temperature) was measured by flow cytometry.  The fold increase of the median 
fluorescence intensity (MFI) relative to the corresponding unstimulated platelets was 
calculated, n = 5-7 mice/genotype.  (B) Representative phalloidin-stained images of resting 
(basal) and thrombin-stimulated (0.1 Unit/ml, 5 minutes) platelets spread on fibrinogen-coated 
cover-slips (100 µg/ml, 45 minutes, 37°C, scale bar: 5 μm).  (C) Mean surface area of 
individual platelets quantified by KNIME software, n = 6 mice/genotype (200 to 450 
platelets/condition). (D) Hemostatic response was measured in saline tail bleeding assay by an 
excision of a 3-mm portion of the tail tip followed by immersion of the tail in 0.9% isotonic 
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saline at 37 °C.  Plotted is the time to complete arrest of bleeding.  Experiments were conducted 
in a double-blinded manner, n = 16 mice/genotype. 
*P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA with Sidak’s test; mean ± SD. 
 
Figure 5.  Partial rescue of Src and Fyn inhibitory tyrosine phosphorylation in TKO 
platelets.  (A) Representative blots of capillary-based immunoassays on lysates of resting 
platelets with the indicated antibodies. (B) Quantification of peak areas, n = 6 mice/genotype.  
*P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA with Sidak’s test; mean ± SD. 
 
Figure 6.  SFKs auto-phosphorylate their C-terminal inhibitory tyrosine residues. 
(A) Representative blots of capillary-based immunoassays on platelet lysates with the indicated 
antibodies.  Lysates were generated from platelets incubated with DMSO, 50 nM dasatinib, 10 
µM PP1, or 3 µM PRT-060318 for 15 min, room temperature. (B) Quantification of peak areas, 
n = 6 mice/genotype.  
Asterisks refer to significant difference compared to DMSO-treated control samples within 
genotypes. *P < 0.05, **P < 0.01, ***P < 0.001, two-way ANOVA with Sidak’s test; mean ± 
SD. 
 
Figure 7.  Revised model of regulation of SFKs in the megakaryocyte lineage. 
(A) Src family kinase (SFK) activity is tightly regulated by the coordinated action of the 
tyrosine kinases Csk and Chk, the receptor-type tyrosine phosphatase PTPRJ, and SFKs 
themselves.  Csk and Chk negatively regulate SFK activity, whereas PTPRJ and SFKs are dual 
positive and negative regulators of SFKs.  (B)  SFKs auto-regulate their catalytic activity 
through the trans-phosphorylation of conserved tyrosine residues in the activation loop and C-
terminal tail.  (C) An equilibrium of different states of SFKs is established in resting and 
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activated platelets through the interplay of these tyrosine kinases and phosphatase, as indicated.  
This is dependent on the concentrations, proximity and catalytic activities of these enzymes. 
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Supplemental Materials and Methods 
 
Flow cytometry 
Platelet surface glycoprotein expression or reticulated platelets were measured in whole blood 
using anti-IIb and indicated antibodies as previously described.1  Resting and PAR4 peptide 
(AYPGKF)-activated platelets were stained with FITC-conjugated P-selectin Ab, TLT-1 
(Alexa Fluor 488) Ab or Alexa488-conjugated fibrinogen, and fixed with 1 % ice-cold 
formalin.  Median fluorescence intensity (MFI) in IIb positive cells or gated population in 
side scatter area (SSC) and forwards scatter (FSC) in 10,000 events was measured by flow 
cytometry (BD Biosciences Accuri C6). 
 
Capillary electrophoresis-based immunoassays 
For quantitative analysis, platelet whole cell lysates (WCLs) were analyzed with an automated 
capillary-based immunoassay platform (Wes, ProteinSimple, San Jose, USA), according to the 
manufacturer’s instructions.  Briefly, WCLs from resting platelets or platelets incubated with 
DMSO, 50 nM dasatinib, 10 M PP1, or 3 M PRT-060318 (for 15 min, at room temperature) 
were diluted to the required concentration with 0.1X sample buffer, then prepared by adding 
5X master mix containing 200 mM dithiothreitol (DTT), 5X sample buffer and fluorescent 
standards (Standard Pack 1, PS-ST01-8) and boiled for 5 minutes at 95°C.  Samples, antibody 
diluent 2, primary antibodies and anti-rabbit secondary antibody, luminol S-peroxide mix and 
wash buffer were displaced into Wes 12-230 kDa prefilled microplates, (pre-filled with 
separation matrix 2, stacking matrix 2, split running buffer 2 and matrix removal buffer, SM-
W004).  The microplate was centrifuged for 5 minutes at 2500 rpm at room temperature.  To 
start the assays, the capillary cartridge was inserted into the cartridge holder and the microplate 
placed on the plate holder.  To operate Wes and analyze results Compass Software for Simple 
Western was used (version 3.1.7, ProteinSimple).  Separation time was set to 31 minutes, 
stacking loading time to 21 seconds and sample loading time to 9 seconds, and for detection 
the High Dynamic Range (HDR) profile was used.  For each antibody, a lysate dilution 
experiment was performed first to confirm the optimal dynamic range of the corresponding 
protein on Wes.  This was followed by an antibody optimization experiment to compare a range 
of dilutions and select an antibody concentration near to saturation level to allow a quantitative 
comparison of signals between samples.  The optimized antibody dilutions and final lysate 
concentrations were as follows (antibody dilution, lysate concentration): Src p-Tyr418 (1:10, 
2 
 
0.05 mg/ml); Lyn p-Tyr507 (1:10, 0.32 mg/ml); Shp1 p-Tyr564 (1:10, 0.32 mg/ml); Shp1 
(1:10, 0.2 mg/ml) and Shp2 p-Tyr580 (1:10, 0.05 mg/ml) were incubated for 60 minutes, 
whereas Src p-Tyr529 (1:100, 0.025 mg/ml); Fyn p-Tyr530 (1:50, 0.025 mg/ml); Src (1:50, 
0.05 mg/ml); Lyn (1:25, 0.05 mg/ml); Fyn (1:25, 0.05 mg/ml); Syk (1:10, 0.00625 mg/ml); 
Shp2 (1:10, 0.00625 mg/ml); Csk (1:10, 0.05 mg/ml); Chk (1:80, 0.2 mg/ml);  GAPDH (1:10, 
0.05 mg/ml) were incubated for 30 minutes. 
 
Immunohistochemistry 
Femurs, spleens and inflated lungs were fixed in buffered formalin and embedded in paraffin.  
Sections were stained with haematoxylin and eosin (H&E), reticulin (Gordon & Sweet) or anti-
CD42b antibody by Advance Histopathology Laboratory Ltd (London UK).  Images were 
obtained by Slide Scanner Axio Scan.Z1 brightfield microscope (Zeiss) and microscope 
(Leica).  MK count analysis in whole section and per field view was performed in a double 
blinded manner. 
 
Static adhesion spreading assay 
Washed platelets were pre-incubated with or without thrombin (0.1 Unit/ml, 5 minutes, room 
temperature) placed on fibrinogen-coated cover-slips as previously described.1  Platelets were 
fixed with 4% formalin, permeabilised by 0.2% Triton X-100 and stained with Alex Fluor 488-
phalloidin.  Platelets were imaged by an Epi-fluorescence microscope (Zeiss) with an x63 oil 
immersion lens.  A semi-automated machine learning based KNIME workflow was used to 
quantify the area of spread platelets as previously described.2  Images were blinded before the 
quantification.  An ilastik pixel classifier was used to produce a binary segmentation.  To 
separate touching platelets, the centre of individual platelets were manually selected using 
KNIME.  These coordinates were used to produce the final segmentation of individual platelets, 
and platelet size and shape were then calculated. 
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Table S1
Hematological analysis of Chk KO, Chk;Csk DKO and Chk;Csk;Ptprj TKO mice.
Parameter Control CKO
PLT (103/µL) 853.1 ± 86.2 896.6 ± 89.6
MPV (fL) 5.3 ± 0.28 5.06 ± 0.18
RBC (106/µL) 9.22 ± 0.55 9.00 ± 0.50
HCT (%) 29.16 ± 1.6 27.83 ± 1.56
WBC (103/µL) 8.79 ± 2.66 7.63± 1.74
LYM (103/µL) 6.79 ± 1.92 5.99 ± 1.81
MON (103/µL) 0.38 ± 0.25 0.08 ± 0.04**
NEU (103/µL) 1.34 ± 0.6 0.53 ± 0.14***
BAS (103/µL) 0.009 ± 0.01 0.002 ± 0.01
DKO
64.4 ± 21.5***
7.91 ±0.35***
7.88 ± 0.33***
26.35 ± 1.46***
8.34 ± 1.95
6.46 ± 1.55
0.22 ± 0.09
0.57 ± 0.20***
0.009 ± 0.01
TKO 
560.3 ± 50.0***
6.53 ±0.43***
8.46 ± 0.43***
26.94 ± 1.36**
7.68 ± 2.66
5.87 ± 1.31
0.32 ± 0.34
0.76 ± 0.48**
0.008 ± 0.01
PLT, platelets; MPV, mean platelet volume; RBC, red blood cells; HCT, haematocrit, WBC, white blood
cells; LYM, lymphocytes; MON, monocytes; NEU, neutrophils; BAS, basophils; CKO, Chk KO
Mean ± standard deviation, n=14, *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA with Sidak’s test
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Figure S1. Defective platelet activation in DKO mice is restored in TKO mice.
Representative plots (A) anti-P-selectin-FITC, (B) anti-TLT-1-FITC and (C) fibrinogen-488
binding to washed platelets (2 x 107/ml) which were either left unstimulated or following
stimulation with PAR4 peptide (AYPGKF) (100 µM or 500 µM, 20 min, room temperature) as
measured by flow cytometry.
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Figure S2.  Normal platelet counts in Gp1ba-Cre;Ptprj and Pf4-Cre;Ptprj KO mice. 
(A) Platelet counts, n = 12 mice/genotype.  (B) Platelet volumes, n = 12 mice/genotype. 
Asterisks refer to significant difference compared to respective controls.  **P < 0.01, 
***P < 0.001, one-way ANOVA with Sidak’s test; mean ± SD.
